Protara Therapeutics has scheduled participation in two investor conferences during the first quarter of 2026, with senior management slated to participate in fireside chat sessions. The biopharmaceutical company will utilize these venues to discuss its pipeline and corporate strategy with institutional investors and market participants.
The company will present updated interim data from its Phase 2 ADVANCED-2 clinical trial evaluating TARA-002 as a treatment for BCG-unresponsive non-muscle invasive bladder cancer at the ASCO Genitourinary Cancers Symposium. The presentation of interim efficacy and safety results represents a key milestone for the therapeutic candidate, which targets a patient population with limited treatment options following standard BCG immunotherapy failure.
These conference appearances provide Protara with opportunities to communicate clinical progress to investors and the healthcare community during a significant period for the company's development program.